Certain essential treatments used in resuscitation, hematology or for immune deficits are now under tension. The National Medicines Safety Agency (ANSM) is launching a national alert and recommends anticipating the shortages to come on several blood derivatives produced by the LFB laboratory.
The drugs concerned by supply tensions
THE French fractionation and biotechnology laboratory (LFB)specializing in the manufacture of blood derived drugs, faces supply difficulties On several critical specialties, according to an announcement published by theANSM July 3, 2025.
The impacted products include in particular: Aclotine (Antithrombine III), Alfastin (alpha-1-antitrypsin), Betafact (factor IX), Factane (factor VIII), Clairyg And Tegeline (immunoglobulins IV), Clottafact (fibrinogen), Protexel (protein C), Vialebex (albumin) and Wilfactin (Von Willebrand factor).
These treatments are essential for patients with immune deficits, hemophilia, severe liver pathologies or requiring a Intensive care in intensive care. Current tensions are due to an industrial modernization phase of the production site in Lille, which should last until Mi -2026.
Limited sales and available alternative solutions
To avoid a sudden rupture, the ANSM has established Distribution restrictions In collaboration with the LFB. Health professionals are invited to favor therapeutic alternatives When they are available.
In its press release, the ANSM stresses that “Therapeutic alternatives are available in sufficient quantity to ensure continuity of care “.
Concerning the Wilfactinkey treatment of patients with Willebrand’s disease, the agency reassures: “The needs may be covered and access to treatment remains guaranteed “.
On the other hand, for products like Clottafactspecial attention is required. Professionals must imperatively verify the Dosage, conservation and administration methodsand systematically refer to Summary of product characteristics (RCP).
A structural situation called to last
The current tension does not fall under a punctual crisis. It is directly linked to a Restructuring of industrial capacities of the LFBin progress on its site of Lille. The objective of this modernization: triple production volumes For immunoglobulins, fibrinogen or albumin.
ANSM anticipates a prolonged fluctuations period On the availability of these products, at least until the summer of 2026. In the meantime, it mobilizes specialized medical networks – in particular the sector Mhemo and the network Allow – in order to strengthen theSupervision of prescriptions and guarantee access to drugs for vital indications.